A prospective study of the usefulness of circulating tumor DNA as biomarker during neoadjuvant chemotherapy for the borderline-resectable pancreatic cancer

A prospective study of the usefulness of circulating tumor DNA as biomarker during neoadjuvant chemotherapy for the borderline-resectable pancreatic cancer - A prospective study of the usefulness of ctDNA as biomarker during NAC for the BR pancreatic cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026647

Enrollment

Registered

2017-04-01

Start date

2017-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

borderline- resectable pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients are planned to treat neoadjuvant chemotherapy according our protocol.

Exclusion criteria

Exclusion criteria: The patients follow our protocol.

Design outcomes

Primary

Measure	Time frame
The correlation of the dose of ctDNA on before and after neoadjuvant chemotherapy and the relapse-free survival	—

Countries

Japan

Contacts

Public ContactYuji Kitahata

2nd department of surgery, Wakayama medical university 2nd department of surgery

yuji-kh@wakayama-med.ac.jp0734410613

Outcome results